Oral semaglutide for Diabetes Mellitus, Type 2

Estimated [adult] diabetes prevalence trends will be presented annually based on nationally representative surveys from different sources, such as the NHANES Program. The estimates of diabetes prevalence may serve as a means of monitor surveillance and evaluating of diabetes control. (Cancer 2010). Diabetes is an important part in health problems because it produces high blood sugar levels that may interfere with the body's ability to process food, or can cause serious complications. Diabetes can come in different forms, such as Type 1 and Type 2. Type 1 is the most common form of diabetes mellitus. Type 2 diabetes mellitus often goes unnoticed until it has already progressed.

In this cross-sectional study of patients with [type 2 diabetes](https://www.withpower.com/clinical-trials/type-2-diabetes), only one-fourth were screened for retinopathy; no other cardiovascular risk factors were measured. This may be because these patients did not recognize their diabetes for many years, and were screened only after a diagnosis of retinopathy was made by a specialist.

Results from a recent clinical trial indicate that genetics, lifestyle, environmental factors, and endocrine milieu play a role in the metabolic abnormalities leading to type 2 diabetes mellitus.

The onset of diabetes can be detected through non-specific symptoms. For patients who are at risk, an oral glucose tolerance test (OGTT) can help detect prediabetes. In addition, HbA1c is helpful in identifying DM2.

With modern therapy, the prognosis of DM, type 2 is improving. Diabetes, type 2 does not seem to be a disease that can definitely be cured; however, it can be controlled and patients still have a good prognosis.

Diabetes, type II is a disease characterized by impaired fasting of blood sugar, increased urinary losses of glucose and ketones, and increased vulnerability to complications because of the disease.

Patients with diabetes should consider clinical trials for NIDDM or T2DM when there is a treatment option that can change the course of their disease, can prevent irreversible damage, or is expected to optimize glucose control and potentially reduce healthcare costs.

This review summarizes recent research on new discoveries for treating diabetes mellitus. This review was based on only a very brief overview of each article and additional research is still necessary to establish any new treatments or drug regimens that may offer promise.

Most patients taking semaglutide met the combination-treatment scenario for HCCA, and a minority of patients taking other medications (not met by patients taking semaglutide alone) underwent adjuvant or new-drug therapy before or after semaglutide. Patients prescribed antiretrovirals, metformin, and a statin used to be more likely to receive additional medical therapies.

Oral semaglutide monotherapy and combination therapy with metformin provided robust reductions in glycaemia without any significant side effects, particularly in T2DM patients. Further studies are warranted with semaglutide in order to determine its potential role for improved glycaemic control in T2DM patients.

In patients with type 2 diabetes, a single dose of oral semaglutide 100 mg is associated with rapid and sustained reductions in HbA1c, HOMA-ins, 2H-Glu, fasting F2-isoprostane, and F2-iso-15:0, but no increase in FFA or LDL cholesterol. The rapid and sustained HbA1c reductions suggest that a single dose of semaglutide may be effective in delaying progression of type 2 diabetes and/or minimizing the consequent cardiovascular disease risk.